Novartis buying Nestle's chunk in Alcon
Essentially, the deal is to happen in two parts. The first stage appears to be a purchase of a 25% stake in Alcon for around $11 billion. This purchase comes with an option to purchase an additional 52% stake for about $28 billion.
Novartis will pay $143.18 a share for the purchase of the 25% stake. The option to purchase the 52% stake will come at a fixed share price of $181 and can come between 2010 and 2011.
From a statement on Nestle's website, the food maker plans to use the proceeds to reduce debt and the cash will also "support opportunities for profitable growth in line with the group's nutrition, health and wellness orientation.''
Zack Miller is the managing editor of IsraelNewsletter.com and a former equity analyst for a leading multinational hedge fund.
Related Posts
- Analyst upgrades: AXP, MET, BK, NYX, PSUN and NVS (39 days ago - 0 Comments)
- Analyst downgrades: AAPL, NVS, WFC, WM and IFX (39 days ago - 0 Comments)
- Analyst downgrades: STX, NT, TJX, NVS and ANN (40 days ago - 0 Comments)
- Novartis (NVS) gets Diovan approval in Canada (53 days ago - 0 Comments)
- Novartis (NVS) blood-pressure drug well-received (2 days ago - 0 Comments)
Add your comments
Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.
When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.
To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br> tags.










